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Abstract
Current literature indicates there is still some debate regarding the scope and severity of
cancer treatment related cognitive impairment (CRCI), with a wide variety of complex factors
contributing to cognitive decline and discrepancies between objective findings and patient selfreport. This paper aims to provide guidelines for neuropsychological evaluation, management,
and rehabilitation of CRCI in breast cancer patients based on current research. This paper also
aims to discuss current research on proposed mechanisms of action for CRCI, the cognitive
domains affected in CRCI, and significant bio-psycho-social risk factors impacting CRCI.
Introduction
“Chemobrain” is a term that has been used by patients to describe declines in cognitive
abilities that coincide with cancer treatment, which may include radiation therapy,
chemotherapy, hormonal therapy, or a combination of these therapies. Recent literature points to
“cancer-related cognitive impairment” (CRCI) as the preferred term, as the former term
“chemobrain” may create an expectation of negative outcome and avoidance for patients making
important treatment decisions (Chao et al., 2021). Increasing evidence over the past 20 years
suggests that treatment for non-central nervous system (non-CNS) cancer can have both acute
and long-term effects on cognitive functioning, which can affect education, occupation, activities
of daily living, and overall quality of life. The prevalence of pre-treatment cognitive impairment
in women with breast cancer is estimated to range from 11% to 35% of patients, which
underlines the important of pre-treatment baseline assessments in studies to accurately detect
changes in cognitive function attributable to treatment (Bradshaw & Wefel, 2014). Longitudinal
studies estimate the incidence of CRCI following systemic chemotherapy treatment in breast and
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brain cancer patients ranges from around 19% to 78% (Bradshaw & Wefel, 2014). More recent
studies have indicated that subjective cognitive complaints are reported in 50% or more of breast
cancer patients following chemotherapy, while 15-25% of those patients demonstrated objective
cognitive decline on testing (Lange et al., 2019). These wide estimates may partly be due to the
use of different neuropsychological tests, reference data, and performance cutoffs for classifying
results between studies (Wefel et al, 2011). Some of this variability may also be related to
differences inherent to primary cancer type, site, and chemotherapy agents used (Noll et al.,
2018). The specific cognitive deficits reported across these studies include attention, learning
and memory, processing speed, and executive function, reflecting a frontal-subcortical profile of
deficits. While many patients will have their cognitive issues subside over time following
treatment, many others continue to experience ongoing, progressive decline following treatment.
Regardless of prevalence estimates, it is generally accepted that a significant portion of
breast cancer patients experience persistent subjective and objective cognitive decline, and thus,
effective detection and management of CRCI is an important goal for healthcare providers in
increasing the quality of life for patients. It is important to note that in the literature objective
impairment refers to demonstrated cognitive impairment with neuropsychological testing, while
subjective impairment refers to patient reported cognitive impairment. This distinction should
not invalidate a patient’s subjective experience of cognitive decline, and there are numerous
important factors that could be contributing to any discrepancy between objective and subjective
decline, such as a lack of sensitivity of neuropsychological tests used in the battery, variations in
the definition of impairment between providers, a lack of neuropsychological testing data on
premorbid cognitive functioning, other health problems, medications, current levels of
psychological distress and imprecise estimates of premorbid functioning (Hutchinson et al.,
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2012). The terms “objective” and “subjective” are somewhat limited in that both patients and
medical providers may infer from the term “subjective” that the patient’s cognitive decline is not
real. In this paper and in the literature, the term “subjective” indicates that a patient’s experience
of cognitive decline was simply not detected on neuropsychological testing, not that it does not
exist or that the patient is misperceiving their reality. It is important for medical providers to be
conscientious of using terms like these with patients to avoid invalidating their experience.
Given the complexity of CRCI, neuropsychologists conducting evaluations for breast
cancer survivors may benefit from this paper as it will provide guidelines for testing,
recommendations, and can help clarify and support clinical impressions. Providing a
comprehensive overview of proposed mechanisms of action of CRCI as well as the bio-psychosocial risk factors that may impact CRCI can help neuropsychologists explain the etiology of
cognitive impairments for patients.
Methods
The scope of this paper will be limited to breast cancer patients and not include research
on CNS patients. A minor portion of relevant research that focuses on non-CNS cancer patients
in general will also be utilized, as breast cancer fits under this umbrella. This narrowing of focus
is due to important differences in typical presentation, course, treatment, and assessment
considerations between these populations. Further, a significant portion of existing literature on
CRCI involves breast cancer patients, which provides a foundation of research and information
from which to build on. A review of peer-reviewed articles will be used to determine guidelines
for neuropsychological evaluation and management of CRCI, bio-psycho-social risk factors, and
proposed mechanisms of action. Literature used in this paper will be limited to articles published
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within the last 12 years. Neuropsychological cognitive domains to be examined include all
domains typically assessed in a neuropsychological assessment; attention and concentration,
processing speed, executive functioning, language skills, visual-spatial ability, working memory,
immediate and delayed verbal and visual memory, and motor functioning.
Proposed Neuropathological Mechanisms involved in CRCI
Accelerated aging has been proposed as a potential mechanism of progressive cognitive
decline in non-CNS cancer patients. Aging is associated with a variety of biological changes that
include DNA damage, oxidative stress, inflammation, and decreased telomere length and activity
(which are located on chromosomes and involved in cell division), and chemotherapy has been
associated with those same biological changes (Ahles et al., 2012). Past research has also
implicated the above processes in the development of neurodegenerative disease and cognitive
decline. Thus, research suggests the biological processes underlying cancer, the impact of cancer
treatment, aging, neurodegeneration, and cognitive decline may all be linked, leading to the
hypothesis that cancer treatments may accelerate the aging process (Ahles et al., 2012).
Significant progress has been made in neuroimaging research on cognitive functions for
breast cancer patients in recent years. Imaging studies have confirmed that chemotherapy is
associated with structural and functional changes, notably in the frontal regions involved in
executive functioning and memory. Studies have shown a reduction in gray matter volume in
frontal brain regions one month after chemotherapy completion when compared to baseline, and
this reduction was associated with higher cognitive complaints in patients (Joly et al., 2015).
Further, this structural change was accompanied by altered brain activation in these areas while
performing a working memory task, which may suggest a decrease in efficiency of cognitive
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function. One study estimated that in long-term brain cancer survivors, these changes in volume
were equivalent to four extra years of aging (Koppelmans et al., 2012). Research exploring the
long-term effects of chemotherapy on brain structure in a large cohort of breast cancer survivors
spanning 20 years after chemotherapy found total brain and global gray matter volumes were
smaller in survivors than in healthy controls, though no significant differences were found in
hippocampal volume or white matter volume and integrity (Joly et al., 2015). However, other
studies have observed white matter pathology in patients that have undergone chemotherapy for
breast cancer. The reduction in white matter integrity is believed to be associated with axonal
degeneration and demyelination evidenced in diffusion tensor imaging (Bradshaw and Wefel,
2014). These findings are significant because a decrease in gray matter volume is associated
with declines in cognitive function, like memory, as well as motor functioning, depending on
where the reductions are most prominent. A decrease in white matter integrity can lead to issues
in areas like speed of information processing and motor skills, while a decrease in hippocampal
volume is associated with learning and memory deficits.
5-fluorouracil (5-FU), a major chemotherapy agent commonly administered to breast
cancer patients, induced an alteration of cognitive flexibility and behavioral reactivity to novelty,
indicating that long-term chemotherapy alters activity of selective brain areas connected to
“hippocampal-cortical-frontal-cerebellar” networks in the dentate gyrus of the hippocampus
(Joly et al., 2015). Research indicates that 5-FU and other cytotoxic drugs currently used in the
treatment of cancer are shown to impact spatial memory, behavioral flexibility, and were
associated with inhibiting proliferation of neural precursors and mature neuron integrity, leading
to a reduction in brain tissue (Joly et al., 2015). Spatial memory deficits can result in difficulty
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navigating to places or remembering the location of an object or event, while a decrease in
behavioral flexibility would result in difficulty adapting to new situations (Lezak, 2012).
Further research in this area suggests that chemotherapy in breast cancer patients causes
alterations in brain metabolites and brain network connectivity similar to processes that occur
with normal aging. Specifically, the alterations in brain connectivity involve disruptions in
frontal, striatal, and temporal areas, as well as reduced global connectivity in breast cancer
patients treated with chemotherapy over healthy controls (Bradshaw and Wefel, 2014). The
areas affected are implicated in executive function and memory, and cognitive dysfunction in
these patients may be linked to disrupted coordination between brain regions, or a “disconnection
syndrome,” with lower white matter integrity and thus decreased processing speed and/or motor
issues (Bradshaw and Wefel, 2014).
Other research in this area has examined the relationship between the body’s
inflammatory response to chemotherapy and cognitive complaints. Research has suggested a
relationship between self-reported memory and attention complaints and immune system
cytokine markers, like tumor necrosis factor alpha and interleukin 6, which are involved in
immune system cell signaling. Brain glucose metabolism is thought to correlate with brain
activity, and changes in metabolism in the medial prefrontal cortex and anterior temporal cortex
of the brain was found to correlate with both memory complaints and cytokine marker levels in
chemotherapy patients (Pomykala et al., 2013).
With respect to hormone therapy, research studies suggest that these treatments act on the
estrogen and androgen receptors in the hippocampus and cerebral cortex. Imaging studies have
demonstrated that women treated with Tamoxifen, a selective estrogen receptor modulator
(SERM), had reduced hippocampal volumes and lower frontal lobe glucose metabolism
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compared with controls and compared with women taking estrogen (Bradshaw and Wefel, 2014).
Studies show that Tamoxifen also appears to affect neurotransmitter (serotonin and dopamine)
and cytokine systems implicated in cognitive functioning. Animal studies in rodents revealed
repeated administration of Tamoxifen or androgen deprivation has been shown to impair
performance in learning and memory (Bradshaw and Wefel, 2014). Clinical research indicates
that administering estradiol within a specific time window can stimulate neuroplasticity and
improve cognition in breast cancer patients treated with SERMs and/or aromatase inhibitors
(Schagen et al., 2014). SERMS and aromatase inhibitors work by blocking estrogen receptors
and estradiol synthesis respectively, thus decreasing estrogen levels in the body.
Animal models have been useful in studying the impact of chemotherapy and cancer on
brain function. Past animal studies support the hypothesis that chemotherapy affects brain
structure and function and provide evidence for candidate mechanisms of chemotherapy induced
cognitive changes (Ahles et al., 2012). Potential mechanisms for the effect of chemotherapy on
the brain that have been demonstrated by animal studies include inhibition of hippocampal
neurogenesis, oxidative damage, white matter damage, decreased hypothalamic-pituitary adrenal
axis activity, and reduced brain vascularization and blood flow (Ahles et al., 2012).
Domains Impacted in CRCI
Research in breast cancer survivors indicates they experience objective impairments in
memory, processing speed, attention, and executive functioning post-chemotherapy (Lange et al.,
2019). Other research has listed the neuropsychological domains most affected as verbal
working memory, psychomotor processing speed, and visual-spatial memory, with cognitive
impairment found in cancer survivors years after completing chemotherapy, in contrast to
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survivors of the same cancer type who did not receive chemotherapy (Ferguson et al., 2012).
The most common cognitive deficits noted among breast cancer survivors include areas related
to executive functions including working memory, cognitive flexibility, multitasking, planning,
and attention. Executive functioning impairment can have a significant downstream effect on
other cognitive domains, like language, social cognition, and declarative memory. Executive
functioning deficits can also have negative impacts on psychosocial functioning, education
achievement, career success, and has been shown to be associated with medication nonadherence (Kesler et al., 2012). These deficits can also lead to decreased self-esteem and selfefficacy.
Literature on subjective impairments has shown cancer survivors self-report problems
with word retrieval, working memory, and increased mental fatigue. Patients may present with
complaints of difficulty with short-term memory concerning conversations or misplacing items,
as well as issues with concentration, organization, and multitasking. (Bradshaw & Wefel, 2014).
Further, this notice of changes can elicit significant distress, anxiety, depression, and past studies
indicate higher levels of emotional distress are correlated to greater severity of self-reported
issues (Chao et al., 2021). Regarding quality of life and daily functioning, numerous studies
indicate that life areas impacted include decreased effectiveness in work-related activities,
caregiving, and driving (Chao et al., 2021). Other studies had reports of individuals who delayed
or deferred educational pursuits, switched employment positions with less responsibility and pay,
left employment, and withdrew from social activity due to fear of appearing cognitively impaired
(Ferguson et al., 2012). With respect to trajectory of cognitive changes, studies indicate most
patients with CRCI report changes during active treatment, 30% demonstrating objective CRCI
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at the completion of chemotherapy, and up to 35% experiencing persistent symptoms in the
months to years following treatment (Chao et al., 2021).
Hormone therapy is commonly used in the treatment of patients with breast cancer and
has been found to negatively affect cognitive functioning, though results have been mixed.
Specifically, breast cancer patients who receive Tamoxifen, a selective estrogen receptor
modulator, Anastrozole, an aromatase inhibitor, or a combination of the two, performed worse
on measures of memory, processing speed, and executive functioning compared to control group
patients. Treatment with luteinizing hormone releasing hormone (LHRH) has also been
associated with declines in visuospatial processing, visual memory, and executive functioning
(Bradshaw and Wefel, 2014). Another study noted that breast cancer patients treated with
Anastrozole had lower executive function scores compared to healthy controls up to 18 months
following treatment, as well as decreased working memory and concentration 12 to 18 months
following treatment (Lange et al., 2019).
A review of literature on CRCI found while evidence shows some cancer survivors
experience cognitive difficulties following chemotherapy, subjective cognitive complaints are
more frequently reported than cognitive deficits shown by objective neuropsychological
assessments (Hutchinson et al., 2012). This study reviewed the relationship between subjective
and objective measures of cognitive impairments following treatment and stated they failed to
consistently find an association between subjective and objective measures of cognition, and this
discrepancy may be partially explained by a lack of sensitivity in neuropsychological tests used,
differing definitions of cognitive impairment between providers, and imprecise estimates of
premorbid functioning. A lack of neuropsychological testing data on the patient’s premorbid
functioning could also be important, in that a patient’s cognitive functioning may have dropped
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from a superior or above average range to a low average range, and while low average would not
be considered cognitive impairment, it is still a significant drop that could lead to understandable
distress for the patient. The authors state that since discrepancies between subjective and
objective impairment may be explained by variations in assessment methods and/or definitions
of impairment, this underlines the need for some standardization of evaluation methods for
CRCI, which will be discussed further in the section on neuropsychological evaluation of CRCI
(Hutchinson et al., 2012). The authors also noted that subjective impairment may be an indicator
of psychological distress rather than cognitive impairment, and that regardless of discrepancies,
the patient’s perceptions of impairment are no less important because they significantly impact
quality of life and significant psychological distress can adversely impact cognition. It is the job
of the neuropsychologist to translate the relative experiences of patients into normative labels of
functioning based on all bio-psycho-social factors, not just test data alone.
Studying cognitive dysfunction associated with chemotherapy is a challenge since
cognitive deficits can be present before the start of treatment, combinations of chemotherapy
drugs can affect cognitive functioning more than others, and not all individuals are equally
affected by the same chemotherapy regimen (Wefel et al, 2011). Variance among studies may
also be due to assessment instruments used and criteria for defining change (Ahles et al., 2012).
Further, lack of pre-chemotherapy evaluations also limits the conclusions that can be drawn from
some of these studies (Ahles et al., 2013).

Table 1. Suspected Cognitive Impairments Induced by Cancer Treatments. Adapted from
(Lange et al., 2019)
Cancer Treatment
Cognitive Domains Affected (objective
impairment on testing)
Chemotherapy:
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Taxol
Methotrexate
Fluorouracil
Hormone Therapy:
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Androgen Deprivation Therapy

Running Head: CRCI IN BREAST CANCER
12

Memory, processing speed, attention and
concentration, executive functioning

Executive functioning, working memory,
concentration, visuomotor functions

Risk Factors Impacting CRCI
Research suggests factors that increase risk of CRCI include premorbid cardiovascular
conditions, older age, and lower cognitive reserve, which is determined by an estimated IQ
derived from test performance, level of education, and demographic information (Chao et al.,
2021). Longitudinal studies revealed that about 20-30% of breast cancer patients have cognitive
impairments before the start of adjuvant treatment, and this is seen more frequently in elderly
patients than younger ones (Joly et al., 2015). Since accelerated aging has been considered a
potential mechanism of CRCI, elderly cancer patients may be particularly susceptible to CRCI in
addition to being at risk for possible co-occurring neurodegenerative processes (Noll et al.,
2018). Cognitive reserve, which represents innate and developed cognitive capacity influenced
by education, occupational attainment, and lifestyle, has been associated with high resiliency to
cognitive decline after brain insult in studies (Ahles et al., 2012). Research has demonstrated
that age, as well as baseline cognitive reserve, are predictors of post treatment cognitive decline
in processing speed among women treated with chemotherapy for breast cancer. Further,
research has indicated that more than 60% of elderly breast cancer patients who report

PATIENTS

Running Head: CRCI IN BREAST CANCER
13

preexisting memory problems are more likely to report worsening memory following
chemotherapy (Joly et al., 2015).
Poor sleep and chronic bone pain, which are common during cycles of chemotherapy, are
also associated with cognitive impairment in cancer patients. Medications taken for these
problems can have side-effects that are associated with cognitive issues as well. Prior studies
have noted 20-70% of breast cancer patients report sleep disturbance, with around 20% meeting
diagnostic criteria for insomnia. Poor sleep has been associated with poorer performance in
attention, memory, working memory, and executive functioning (Chao et al., 2021). Prior
research shows prescribed sleep medications such as Zolpidem demonstrate mild to moderate
negative effects on verbal memory, attention, processing speed, and working memory, while
Trazadone has been found to mildly impact short-term memory (Stranks et al., 2014). It is
estimated that 33-64% of patients experience cancer related chronic pain, which has been
associated with worse performance in attention and executive functioning. Further, up to twothirds of patients with cancer have reported their functional independence is significantly
impacted by pain (Chao et al., 2021). Opioids, tricyclic antidepressants, and anti-convulsant
medication taken for pain have all been associated with a decrease in cognitive performance,
though results have been variable. Specifically, opioids have been associated with impairments
in attention and concentration, memory, visuospatial skills, and psychomotor speed, and past
studies suggest that a significant portion of breast cancer patients are prescribed opioid
medication (Gruber et al., 2007). One study found that among about 25,000 patients with breast
cancer included in the study sample, 46.8% had an opioid prescription during the one year prior
to metastatic breast cancer diagnosis. During the one year after metastatic breast cancer
diagnosis, 81.4% of patients received at least one opioid prescription, while 55.8% had at least
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three opioid prescription claims, and 22.8% had at least seven filled opioid prescriptions (Shen et
al., 2020).
There are several other medical issues that may contribute to CRCI as well. Anti-emetic
medications prescribed to manage cancer treatment induced nausea and vomiting are not
typically associated with cognitive impairments but are known to cause drowsiness. Further,
corticosteroids used during treatment for nausea, vomiting, and suppressing the immune system
have been found to have modest but significant negative effects in memory and executive
functioning, and are also associated with insomnia (Chao et al., 2021). Diabetes and
cardiovascular disease are associated with impairment among patients before adjuvant
treatments, which underlines the importance of including a comprehensive assessment of
comorbidities in future studies (Joly et al., 2015). Thyroid dysfunction and anemia, which are
common during active treatment for cancer, have both been known to impact cognitive
functioning in the general population. Genetic factors like apolipoprotein E (APOE4) were
implicated as risk factors for chemotherapy-induced cognitive decline among breast cancer
survivors (Joly et al., 2015).
Research studies have put forth the hypothesis of a dose-response relationship between
chemotherapy and cognitive impairment in breast cancer patients. When controlling for baseline
performance, age, education, and mood, one study found cognitive function progressively
worsened with cumulative chemotherapy exposure (Joly et al., 2015). Another study observed
that cognitive decline rates were higher in patients following high-dose chemotherapy compared
to patients given conventional dose chemotherapy (Schagen et al., 2014). Administration of
chemotherapy via intrathecal or intra-arterial methods may also be associated with increased risk
of CRCI (Bradshaw and Wefel, 2014).
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Mental Health Factors Impacting CRCI
Mental health factors impacting self-reported CRCI include greater baseline levels of
anxiety, depression, and younger age. Additionally, research has shown that patients who were
informed of the potential impact of chemotherapy on cognition were more likely to report higher
levels of cognitive complains, while patients who reported not being educated on the possibility
of CRCI prior to treatment noted higher levels of emotional distress following onset of cognitive
symptoms (Chao et al., 2021). This phenomenon may suggest a “nocebo effect,” a situation in
which a patient’s negative expectations regarding treatment cause the treatment to have a more
negative effect than it otherwise would.
Due to the life-threatening context of the illness, cancer and its treatments can involve
many stressful events and psychiatric symptoms like those reported in depression, anxiety, or
post-traumatic stress disorder, which are known to induce adverse effects on cognition (Joly et
al., 2015). Anxiety, depression, and fatigue frequently occur in cancer patients, and these
variables should be considered in cognitive assessments, as several studies show associations
between cognitive complaints and depression, anxiety, and PTSD (Lange et al., 2019). One
study examined the mental health effects for breast cancer patients undergoing treatment,
including surgical resection, chemotherapy, radiation therapy, or a combination of these
treatments. The study found 38.2% met criteria for depression while 32.2% met criteria for
anxiety based on a structured questionnaire and PHQ-2 and GAD-2 screeners, with other studies
and systematic reviews having found results similarly in the 30-40% range for anxiety and
depression (Tsaras et al., 2018). Further, studies indicate up to 70% of breast cancer survivors
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report clinically significant fear of cancer recurrence, which is characterized by intrusive
thoughts, substantial distress, and maladaptive coping (Johns et al., 2019).
Neuropsychological Evaluation of CRCI patients
Literature on neuropsychological evaluation of cancer patients stress that during clinical
interview and record review, efforts should be made to gather information regarding the onset
and course of cognitive symptoms and how that timeline relates to the patient’s cancer diagnosis
and treatment. A robust understanding about the impact of specific cancers and treatments on
cognition, with close examination of a patient’s known risk factors and neuropsychological
profile can help distinguish between cancer-related and other etiologies of cognitive impairment
(Bradshaw & Wefel, 2014). CRCI is often observed alongside various other symptoms and
issues, including fatigue, chronic pain, multiple strong medications, poor sleep, and emotional
distress, and these comorbidities may impact test engagement and patient quality of life.
Neuropsychologists are uniquely positioned to examine cognitive issues and other important biopsycho-social contributors to patient well-being, thus identifying targets for intervention to
improve overall quality of life (Noll et al., 2018).
Pre-treatment baseline evaluations for breast cancer patients undergoing chemotherapy
provides a valuable point of comparison both in research and clinical practice. Baseline data
helps to determine whether cognitive impairments are attributable to a specific treatment or are
secondary to the cancer itself. Baseline data also allows for identification of subtle treatment
related neurotoxicity for a patient who exhibits a meaningful post-treatment decline but
continues to perform in the non-impaired range relative to normative expectations (Bradshaw &
Wefel, 2014). However, in clinical practice, such baseline data is rarely available as a point of
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comparison. Instead, neuropsychologists are usually presented with referral questions in the
aftermath of cancer treatment without pretreatment data, and thus, pre-morbid level of
functioning must be estimated based on education, occupational attainment, and
neuropsychological tests that are robust to neurological insult and thus can predict level of
functioning before the insult (Bradshaw & Wefel, 2014).
An example of such a test would be the Test of Premorbid Functioning, a revised and
updated version of the Wechsler Test of Adult Reading (Noll et al., 2018). With respect to
neuropsychological evaluations during or post treatment, this will vary depending on the
patient’s treatment course, functional status, and goals. Evaluation shortly after post-treatment
recovery provides an opportunity to offer recommendations for rehabilitation planning or
homecare needs. Timing evaluations in conjunction with patient goals and activities, like return
to work evaluations, ensure that neuropsychological care is given at times of greatest need for the
patient (Bradshaw & Wefel, 2014). It is important for the neuropsychologist to use best
judgment and collaborate with the patient on determining when it is most appropriate to test,
whether it be medical, psychological, or motivation factors that are impacting a patient’s ability
to put forth their best possible effort on testing.
Regarding neuropsychological tests, reliable, valid measures that are sensitive to subtle
changes but robust to practice effects are crucial, since patients may be evaluated numerous
times given the dynamic nature of cancer and treatment (Noll et al., 2018). Re-evaluation in
relatively shorter time intervals than other patient populations and use of alternate forms to
reduce practice effects are also recommended. In test selection, important factors to consider
include a patient’s disease status, expected prognosis, and physical stamina (Noll et al., 2018).
For patients with short-estimated survival time, an extensive battery spanning many hours would
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not be warranted or recommended, and an abbreviated battery tapping key cognitive domains
would be indicated (Bradshaw & Wefel, 2014). For neuropsychological testing with non-CNS
cancer patients, heavy emphasis on testing of frontal and subcortical network functioning is
indicated, which includes executive functioning, processing speed, motor coordination speed,
and learning and memory retrieval.
The International Cognition and Cancer Task Force in 2012 identified a brief core set of
measures that meet the criteria discussed above, are appropriate for both CNS and non-CNS
cancer patients, and can be supplemented with additional measures (Bradshaw & Wefel, 2014).
The ICCTF test battery includes the Hopkins Verbal Learning Test-Revised (HVLT-R), Trail
Making Test (TMT), and the Controlled Oral Word Association of the Multilingual Aphasia
Examination (COWA) (Wefel et al., 2011). The HVLT-R measures learning and memory, has
adequate psychometric properties (i.e., reliability, validity), six alternate forms, and is translated
in several languages. The TMT also has adequate psychometric properties, is not language
dependent, has instructions translated in several languages, and measures psychomotor speed and
executive functioning. The COWA is a measure of speeded lexical fluency which requires
aspects of executive function, has adequate psychometric measures, and one alternate form.
Neuropsychologists are encouraged to supplement this core battery with additional tests of
working memory capacity based on their own preferences, since none of the available measures
meets all the criteria outlined above (Wefel et al., 2011).
Noll et al. expanded on this battery by identifying several tests and measures that provide
“a repeatable core battery with robust psychometric properties” for each cognitive domain (Noll
et al., 2018, pg. 348). The tests for each domain are located in Table 1 below. Literature on test
selection for CRCI stress that no test battery will be appropriate for every cancer patient, thus
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flexibility around these core tests and measures is often necessary, with supplementation and
adjustment varying according to comorbidities, diagnoses and referral questions. Further, tests
with greater sensitivity, like continuous performance tests, are often supplemented, as deficits
can be relatively subtle in some cases (Noll et al., 2018). Validity testing throughout the battery
are also important in gauging patient engagement and effort, and Table 1 provides examples of
short stand-alone and embedded validity measures that can be used in the battery.
A neuropsychological evaluation should also include an assessment of affective
functioning and quality of life, which are commonly compromised in this patient population and
can negatively impact subjective, self-reported cognitive functioning (Noll et al., 2018). It is
notable that self-report of cognitive complaints has been shown to correlate more strongly with
fatigue and mood disturbance than with objective evidence of cognitive dysfunction. Affective
assessment should include assessment of suicidal ideation, as research suggests that the suicide
risk of patients diagnosed with cancer is approximately two times higher than the general
population, and increased risk of suicide can remain for up to 15 years after diagnosis (Bulotiene
& Pociute, 2019). More extensive psychological testing can be administered if a mental health
disorder or condition is indicated, like the Personality Assessment Inventory (PAI) or Minnesota
Multiphasic Personality Inventory (MMPI). However, due to the length of these assessments, it
may be beneficial to schedule these additional assessments on a different day to avoid patient
fatigue.
As discussed previously, the broad estimates in prevalence of objective CRCI may be in
part due to differences in neuropsychological test selection and reference data, but also
differences in performance cutoffs for classifying results between studies (Wefel et al, 2011).
The American Academy of Clinical Neuropsychology (AACN) noted that no universally
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accepted system exists for assigning qualitative descriptors to scores in specific ranges, and the
definition of the term “impairment” also lacks specificity and consensus. To address this, the
AACN organized a consensus conference in which to recommend a universal system of
qualitative labels to describe results and a definition of impairment (Guilmette et al., 2020). It
may be beneficial for future research studies on CRCI to adhere to a similar core battery of tests
like the one proposed in Table 1 and uniform labeling of performance test scores outlined by the
American Academy of Clinical Neuropsychology consensus statement, as this will allow for a
more streamlined comparison of results across studies.

Table 2. Core Battery for Assessment of Cognition in Cancer Patients (adapted from Noll et al.,
2018).
Domain
Test
Premorbid Functioning
Wechsler Test of Adult Reading
Validity
Rey-15, DCT, RDS
Memory
Hopkins Verbal Learning Test – Revised
Brief Visuospatial Memory Test – Revised
Language
Boston Naming Test
MAE: Controlled Oral Word Association
MAE: Token Test
Attention/Processing Speed
WAIS-IV Digit Span
WAIS-IV Arithmetic
WAIS-IV Coding
WAIS-IV Symbol Search
Trail Making Test Part A
Executive Functioning
Visuospatial
Motor
Mood/Symptoms/Quality of Life

WAIS-IV Similarities
Trail Making Test Part B
WAIS-IV Block Design
Grooved Pegboard
Beck Depression Inventory – II
Beck Anxiety Inventory
EORTC QLQ C30/BN20
Insomnia Severity Index (ISI)
PROMIS Pain Interference – Short Form
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Additional Measures
Auditory Consonant Trigrams
Letter Number Sequencing (WAIS)
Paced Auditory Serial Addition Test
(PASAT)
Brief test of attention
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Domains Assessed
Working memory, executive function,
complex attention

Management and Rehabilitation of CRCI
Recommendations for management and rehabilitation of CRCI can vary greatly between
patients depending on referral questions and overall profile. Research has shown that patients
who demonstrate cognitive impairment can benefit from education and instructions on
implementing environmental modifications, external aids, and internal strategies for optimizing
cognitive functioning (Noll et al., 2018). For patients displaying more severe cognitive
impairment, neurological rehabilitation is also commonly recommended, as well as home health
services where cognitive impairment limits self-care. Research has demonstrated that depression
and anxiety disorders are the most frequent psychiatric comorbidities in cancer patients (Mehnert
et al., 2014). As such, individual psychotherapy, like CBT and other evidence-based
psychological interventions, can be beneficial for patients (Noll et al., 2018). Further, to address
potential fatigue and sleep disturbances that are commonly seen in this patient population,
education regarding sleep hygiene and pacing, as well as referrals to sleep clinics when
appropriate, may yield cognitive and quality of life benefits (Noll et al., 2018). For cancer
patients with fatigue and cognitive impairment, participating in regular cardiovascular exercise
has been shown to elicit improvement in cognition and energy levels (Mustian et al., 2012). In
addition to the above recommendations, other more generalized recommendations may be useful
for CRCI patients depending on their overall clinical picture, which include referrals for
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neuroimaging, pharmacological interventions, workplace or academic accommodations,
occupational, physical or speech therapy, and recommendations on decision making or driving
capacity (Noll et al., 2018). The sections below discuss current literature on interventions for
management and rehabilitation of CRCI; cognitive rehabilitation, cognitive behavioral therapy,
acceptance and commitment therapy, physical exercise, mindfulness-based stress reduction, and
behavioral health apps. Though research is ongoing, it should be noted that many of the studies
currently available on the management of CRCI have methodological limitations that include
lack of an active control group for comparison, small sample sizes, and selective reporting of
findings, thus, study findings should be interpreted with caution (Chao et al., 2021).
Many of the interventions discussed below can be provided by a health psychologist
specializing in psycho-oncology as part of a multidisciplinary treatment team. If a patient is not
already connected to a health psychologist and is open to it, this would be an important
recommendation/referral, since addressing the psychological factors contributing to cognitive
impairment can lead to significant improvement.
Cognitive Rehabilitation
Cognitive rehabilitation broadly refers to improving cognitive capacity through skills
training with progressively increasing levels of difficulty, as well as compensatory strategies,
with the goal of maximizing daily functioning. Cognitive rehabilitation can occur in an
individual or group treatment setting, and sometimes can include computer or web-based
programs (Chao et al., 2021). Programs designed specifically for treating CRCI include
components of cognitive behavioral therapy involving psychoeducation, emotional coping skills,
and stress reduction techniques. A recent systematic review in 2021 found that participants
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engaged in cognitive rehabilitation programs experienced objective improvements in at least one
cognitive domain, including memory, executive function, and processing speed (Chao et al.,
2021).
Cognitive training in either memory or speed of processing in breast cancer survivors
demonstrated improvement in memory and processing speed at two months follow up compared
to a control group. Both interventions were also associated with improvement in perceived
cognitive functioning, distress from cognitive symptoms, and quality of life (Von Ah et al.,
2012). Another computerized cognitive training program to improve executive functioning over
12 weeks for breast cancer survivors who were, on average, six years out from completing
chemotherapy, found significant improvements in cognitive flexibility, verbal fluency,
processing speeds, with marginal improvements in verbal memory. Self-reported cognitive
improvements were also reported for executive function skills (Kessler et al., 2013). Attention
retraining and instruction in the use of compensatory strategies, including memory aids like
notebooks, phone alerts, and medication reminder systems to facilitate recall of important
information, showed promise in addressing mental fatigue and cognitive complaints (Bradshaw
and Wefel, 2014). A four-week cognitive rehabilitation program aimed to improve cognitive
function and quality of life in patients after completion of cancer treatment found the program
was effective in improving overall cognitive function, visuospatial constructional performance,
and delayed memory that went beyond practice effects, when compared to non-cognitive
rehabilitation and control groups. The program was also helpful in reducing patients’
perceptions of cognitive impairment and psychosocial distress, as well as promoting social
functioning and understanding of cognition (Schuurs and Green, 2013).
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A Memory and Attention Adaption Training (MAAT) program described as a brief cognitivebehavioral approach designed to help cancer survivors learn and apply adaptive strategies to
reduce the negative functional and quality of life impact of cognitive problems found participants
significantly improved relative to controls on verbal memory and on the quality of life measure
(Ferguson et al., 2012). Another cognitive rehabilitation pilot program for breast cancer
survivors that consisted of five, weekly, two-hour sessions involving psychoeducation, in-group
and home cognitive exercises, and goal setting found significant changes from baseline for motor
and psychomotor speed tests. There were also improvements in self-report assessments of own
functioning, with all cognitive functions except motor speed remaining significant two and four
months after intervention (Ercoli et al., 2013). Altogether, these results suggest that cognitive
rehabilitation can be an effective intervention for objective and subjective cognitive impairment
in cancer patients.

Cognitive Behavioral Therapy
Cognitive behavioral therapy (CBT) is a psychotherapy approach that focuses on
unhelpful thought patterns and behaviors and is commonly used in conjunction with cognitive
skills training within cognitive rehabilitation programs. One study showed self-reported
improvements in memory at six months follow up for a brief, manualized, individual therapy
program that addressed symptom management, communication with healthcare providers,
changes in self and relations, sense of meaning and purpose, and concerns for mortality and the
future (Chao et al., 2021).
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CBT was also shown to be effective in treating depression, anxiety, sleep disturbance,
and chronic pain, which are all factors suspected to contribute to CRCI symptoms. One metaanalysis study found skills training and education had a medium-size effect in reducing pain
severity in cancer survivors (Gorin et al., 2012). Another meta-analysis study found Cognitive
Behavioral Therapy for Insomnia (CBT-I) for cancer survivors with insomnia to significantly
improve sleep efficiency, sleep latency, and wake after sleep onset relative to control conditions
from pre to post intervention, with medium effect size (Johnson et al., 2016). The study also
noted that large effect sizes were observed for self-reported insomnia severity for patients who
received CBT-I, and effects were durable up to six months. The authors concluded that evidence
supports a strong recommendation for the use of CBT-I among cancer survivors (Johnson et al.,
2016).
Acceptance and Commitment Therapy
Acceptance and Commitment Therapy (ACT) is designed to maximize psychological
flexibility in navigating difficulties and challenges in life, and emphasizes acceptance while
living mindfully according to one’s values (Hayes et al., 2011). Fear of cancer recurrence (FCR)
can be a persistent and disruptive problem for many cancer survivors leading to reduced quality
of life, and studies have shown that FCR affects up to 70% of breast cancer survivors (Johns et
al., 2019). Past research has suggested that ACT may improve distress symptoms and quality of
life in cancer patients, but there are few studies to date that have examined the effectiveness of
ACT for FCR. A pilot study by Johns et al. conducted a trial for breast cancer survivors
participating in either a group-based ACT intervention, survivorship education intervention, and
enhanced usual care for breast cancer survivors with FCR. The ACT intervention was designed
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to increase adaptive coping through acceptance, cognitive defusion, mindfulness, and perspective
taking exercises while supporting the participant in aligning behavior with personal values
(Hayes et al., 2013). The ACT group consisted of six, weekly, two-hour sessions, that included
mindfulness exercises each session to develop awareness of the present moment, along with
adaptive strategies for responding to FCR. The survivorship education intervention had a similar
group format and time commitment and involved symptom management, weight management,
physical activity, and survivorship care plans. The enhanced usual care participants continued
receiving standard care from their health care providers and received a National Cancer Institute
booklet with a list of supplemental resources and a review of strategies to manage physical
changes, feelings, and social and working relationships (Johns et al., 2019). Outcomes were
measured using the Fear of Cancer Recurrence Inventory, and the study found the ACT group
demonstrated significant improvement regarding FCR severity while the SE and EUC groups
showed minimal changes across outcomes. The authors state that although preliminary, these
results suggest ACT is a promising intervention for reducing FCR in breast cancer survivors,
particularly regarding reducing avoidant/maladaptive coping (Johns et al., 2019).
Physical Exercise
Animal model studies on physical exercise and CRCI suggest that exercise can promote
neuroplasticity and reduce the effects of chemotherapy on cells in the hippocampus (Chao et al.,
2021). A randomized controlled trial in breast cancer survivors showed improved cognitive
processing speed following an exercise program, though this result was limited to survivors with
diagnoses in the past two years. Another study compared a group of cancer survivors that
underwent a 12-week high intensity interval training (HIIT) exercise program, a group of cancer
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survivors that underwent a moderate intensity continuous (MOD) exercise program, and a waitlist control group (Northey et al., 2019). The study indicated that both the HIIT and MOD
groups demonstrated improvement in executive function and working memory, with a large
effect size for the HIIT group and a medium effect size for the MOD group. Notably, this
particular study only included patients within two years of diagnosis and had a relatively small
sample size (Chao et al., 2021). A recent study compared cognitive function in sedentary breast
cancer survivors randomized to either a 12-week exercise program or a wait-list control group.
The exercise group set specific goals with a clinical psychologist to gradually increase aerobic
exercise to at least 150 minutes of moderate to vigorous physical activity per week, and were
monitored by a Fitbit device throughout the 12 weeks (Hartman et al., 2018). The exercise
program group demonstrated objective neurocognitive improvements in processing speed for
those diagnosed within the previous two years, as well as a reduction in cognitive symptoms
(Hartman et al., 2018). Another study of cancer survivors randomized to eight sessions of yoga
or a control group showed improvements in cognitive complaints in the yoga group (Lange et al.,
2019).
Overall, research suggests physical exercise may be useful for processing speed,
executive function, and working memory for cancer survivors with diagnoses within the past two
years. There is also evidence that exercise can have a positive impact for cancer-related fatigue
and quality of life.
Mindfulness Based Stress Reduction
Mindfulness-based stress reduction (MBSR) utilizes guided mindfulness and meditation
practices focused on improving attentional control and enhancing self-awareness and awareness
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of one’s environment. MBSR has been a treatment of interest for cancer and many other illness
related quality of life problems for patients for many years, and several studies have shown some
effectiveness for improving psychological distress.
A recent meta-analysis investigated MBSR and cognitive function among breast cancer
survivors. This study focused on research that used a MBSR program similar to the one
developed by Kabat-Zinn specifically for chronic pain and anxiety, but modified for breast
cancer survivors (Cifu et al., 2018). This modified program, referred to as MBSR(BC) involves
two-hour sessions for six to eight weeks that focus on controlling and self-regulating attention to
help control and reduce stress and associated symptoms. Participants are given education
materials on mind-body practices, meditations, and instructed to practice 15 to 45 minutes of
formal meditation six days a week, as well as 15 to 45 minutes of informal meditation while
doing usual activities like walking or eating (Cifu et al., 2018). Attention on breathing, focused
body-scans, yoga, and walking meditation are also emphasized as mind-body practices.
Participants are also given audio recordings of daily, guided meditations and asked to keep a
daily meditation diary. MBSR(BC) programs were instructed by doctoral level clinical
psychologists or physicians with MBSR experience, and most groups ranged from 10 to 15
participants (Cifu et al., 2018). The investigators found that MBSR showed some evidence for
improving cognition among breast cancer survivors, but further research using validated and
comprehensive cognitive assessments is required, as well on the timing, duration, and content of
mindfulness interventions (Cifu et al., 2018). Another meta-analysis by Cramer et al. on MBRS
for breast cancer patients came to similar conclusions, in that there is some evidence for the
effectiveness of MBSR in improving psychological health, and existing data was promising, but
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evidence was limited by shortcomings in methodology, and more rigorous research was needed
(Cramer et al., 2012).
Behavioral Health Apps
Further, there are several mindfulness-based apps currently available to the public, such
as Headspace, Calm, and the VA-based Covid-Coach and CBT-I Coach, though academic
research is currently limited on evaluating the effectiveness of these applications. However,
some studies are currently in progress examining the effectiveness of these applications, and a
pilot study has indicated that a mindfulness and relaxation app intervention for cancer patients
was feasible, with acceptable adherence and largely positive feedback from patients (Mikolasek
et al., 2018).

Cultural and Ethnic Diversity Considerations
Literature indicates more research is needed on the psychosocial impacts of breast cancer
for women from diverse ethnic and socioeconomic backgrounds. Studies suggest that cultural
stigmas, taboos, and myths about cancer, as well as cultural competence in health care providers,
can significantly impact cancer treatment (Daher, 2012). A qualitative study involving breast
cancer survivors that included Black, Asian, Latinx, and White participants found differences in
specific beliefs about breast cancer etiology, particular among older and less acculturated
participants. For example, some women considered cancer to be contagious, or caused by breast
trauma. Some held strong spiritual beliefs that the diagnosis was willed by God or a form of
divine punishment, or took a fatalistic attitude towards their diagnosis (Ashing-Giwa et al.,
2004).
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Across all participants, survivors expressed similar fears regarding recurrence, survival,
pain, and loss of autonomy. Fears about changes in body image, scarring, and the effect of
chemotherapy and surgery were also areas of concern. Many survivors described negative
feelings about their bodies after breast cancer treatment, with common sentiments including
decreased self-worth and attractiveness, inadequacy, embarrassment, sadness, frustration, and a
sense of loss. Concerns about the diagnosis affecting their roles as caregivers and the impact on
their families were also important. Black women expressed specific fears related to unfamiliarity
with breast cancer as well as racism within the health care system. Latinx, Black, and Asian
American women also noted they experienced barriers and/or discriminatory treatment in
accessing care (Ashing-Giwa et al., 2004).
In considering cultural and ethnic diversity factors, it is important to note that every
individual experiences their culture and ethnicity differently. These identifiers are informative,
but not defining, and part of the overall picture. The information above demonstrates that being
aware and sensitive to cultural diversity considerations when providing care, educating the
patient and family about expected symptoms and their management, clarifying information about
interventions, and facilitating patient and family communication with the care team are vital for
providers working with cancer patients. It is also important to note that not every patient will be
as open to or willing to engage in western medicine interventions.
Conclusions
Though research in this area is ongoing, proposed mechanisms of action regarding CRCI
include an acceleration of the aging process through DNA damage, oxidative stress,
inflammation, and decreased telomere length and activity (Ahles et al., 2012). Neuroimaging
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indicates structural and functional changes in frontal brain regions, with reductions in gray
matter volume and white matter integrity (Joly et al., 2015). Hormone therapy acting on
estrogen receptors has been associated with reduced hippocampal volumes, reduced
neurogenesis, and decreased frontal lobe glucose metabolism (Bradshaw and Wefel, 2014).
Research on CRCI in breast cancer patients points to demonstrated cognitive impairments
on neuropsychological testing in attention, learning and memory, processing speed, and
executive function, reflecting a frontal-subcortical profile of deficits (Lange et al., 2019).
Common cognitive deficits are in areas related to executive functions, including working
memory, cognitive flexibility, multitasking, planning, and attention (Ferguson et al., 2012).
Executive functioning impairment can have a significant downstream effect on other cognitive
domains and can also have negative impacts on psychosocial, education, and career functioning
(Kesler et al., 2012). Studies indicate the majority of patients with CRCI report changes during
active treatment, 30% demonstrate objective CRCI at the completion of chemotherapy, and up to
35% experiencing persistent symptoms in the months to years following treatment (Chao et al.,
2021).
Risk factors involved in objective CRCI include cognitive reserve, premorbid IQ,
premorbid cardiovascular conditions, older age, poor sleep, chronic pain and fatigue, pain and
sleep medications, thyroid dysfunction, anemia, genetic factors (APOE4), and higher dosing or
repeated exposure to chemotherapy (Ahles et al., 2012; Chao et al., 2021; Joly et al., 2015; Noll
et al., 2018). Risk factors involved in subjective CRCI include emotional status and younger
age. Patients informed of the potential negative impact of chemotherapy on cognition tended to
report higher levels of cognitive complaints, while those not given education on the possibility of
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CRCI reported higher levels of emotional distress following onset of symptoms (Chao et al.,
2021).
Current guidelines on neuropsychological evaluation of CRCI state that pre-treatment
baseline evaluations can provide valuable points of comparison to help determine the etiology of
cognitive issues (Bradshaw & Wefel, 2014). Evaluations during or post-treatment will vary
depending on the patient’s treatment course, functional status, and goals. Evaluation shortly
after post-treatment recovery provides an opportunity for rehabilitation planning and/or
homecare needs (Noll et al., 2018). Timing evaluations in conjunction with patient goals and
activities, like return to work evaluations, ensure that neuropsychological care is given at times
of greatest need for the patient (Bradshaw & Wefel, 2014). It is important for the
neuropsychologist to use best judgment and collaborate with the patient on determining when it
is most appropriate to test, whether it be medical, psychological, or motivation factors that are
impacting a patient’s ability to put forth their best possible effort on testing.
Regarding test battery, reliable, valid measures that are sensitive to subtle changes are
indicated. Re-evaluation in shorter time intervals and the use of alternate forms to reduce
practice effects are also important (Noll et al., 2018). An abbreviated battery tapping key
cognitive domains of frontal and subcortical functioning is indicated, including executive
functioning, processing speed, motor coordination speed, and learning and memory retrieval
(Bradshaw & Wefel, 2014). A recommended test battery adapted from The International Cancer
and Cognition Task Force and subsequent literature on CRCI testing is provided above in Table
2. Assessment of emotional functioning and quality of life should also be included in a test
battery (Noll et al., 2018). The American Academy of Clinical Neuropsychology recommends a
universal system of qualitative labels to describe results and define impairment, which can allow
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for more streamlined comparison of results across studies on CRCI (Guilmette et al., 2020).
During interview and record review, information on onset and course of cognitive symptoms,
timeline of cancer diagnosis and treatment, risk factors, and comorbidities should be gathered.
Neuropsychologists are uniquely qualified to measure cognitive changes, evaluate the impact of
bio-psycho-social factors, provide educational information, and make broad recommendations
beyond the medical treatment (Bradshaw & Wefel, 2014).
In communicating with patients, clinicians should be mindful of using terms like
objective or subjective impairment so as not to invalidate or otherwise impact the patient.
Providers should explain to patients that there may be a number of significant factors that can
contribute to discrepancies between objective and subjective decline, and communicate that the
patient’s perceptions of impairment are no less important, as they significantly impact quality of
life and can adversely impact cognition.
Research on management and treatment of CRCI suggest that cognitive rehabilitation
programs have shown that patients experience objective improvements in at least one cognitive
domain, as well as improvements in subjective complaints. CBT has been shown to be effective
in treating subjective complaints, depression, anxiety, sleep disturbance, and chronic pain related
to CRCI (Chao et al., 2021). Preliminary results suggest ACT may be a viable intervention for
reducing fear of cancer recurrence in breast cancer survivors, particularly in regard to reducing
avoidant or maladaptive coping behaviors (Johns et al., 2019). Physical exercise may be useful
for processing speed, executive function, and working memory for cancer survivors, especially
those with diagnoses within the past two years. There is also evidence that exercise can have a
positive impact for cancer-related fatigue and quality of life (Chao et al., 2021). Mindfulness
based stress reduction has been a treatment of interest for cancer-related quality of life problems
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and several studies have shown some effectiveness in reducing psychological distress (Cifu et
al., 2018). Health psychologists specializing in psycho-oncology can be great assets in a
multidisciplinary treatment team in delivering the above interventions to cancer patients.
Ultimately, the goal is to help patients maintain independence, dignity, cultural or
spiritual practices, and hope in the face of their illness. It is important for neuropsychologists to
partner with the patient, health psychologist, support system, and other healthcare providers to
maximize cognitive functioning and quality of life. Further research is needed to determine the
significant risk factors and appropriate interventions for CRCI, generally with more diverse
demographic populations, larger sample sizes, adequate power, and appropriate control groups.
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